Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11008209 | 0.93 | MAPK1 (0.43) | MAPK1ALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL11003669 | 0.91 | MAPK1 (0.42) | MAPK1OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL131020 | 0.90 | MAPK1 (0.47) | MAPK1SIGMAR1MAPTTHRBOPRM1 | |
| SCHEMBL863778 | 0.89 | MAPK1 (0.43) | MAPK1OPRM1OPRL1MPOTRIM24 | |
| SCHEMBL863645 | 0.87 | MAPK1 (0.42) | MAPK1OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL131067 | 0.86 | SMN1; SMN2 (0.44) | MAPK1MAPTOPRL1MEN1KMT2A | |
| SCHEMBL132371 | 0.86 | MAPK1 (0.43) | MAPK1SIGMAR1THRBTSHR | |
| SCHEMBL30761740 | 0.85 | MAPK1 (0.41) | MAPK1OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL30475621 | 0.85 | MAPK1 (0.41) | MAPK1OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL5250892 | 0.84 | MAPK1 (0.43) | MAPK1OPRM1OPRL1MPOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315748-B1 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYLIC ACID METHYL ESTER AND DERIVATIVES THEREOF | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| EP-2315748-B1 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYLIC ACID METHYL ESTER AND DERIVATIVES THEREOF | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| EP-2650284-A1 | Heterocyclic derivatives as metabotropic glutamate receptor modulators | Merz Pharma GmbH & Co. KGaA (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8084487-B2 | Processes for the preparation of 4-oxo-octahydro-indole-1-carbocyclic acid methyl ester and derivatives thereof | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084487-B2 | Processes for the preparation of 4-oxo-octahydro-indole-1-carbocyclic acid methyl ester and derivatives thereof | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084487-B2 | Processes for the preparation of 4-oxo-octahydro-indole-1-carbocyclic acid methyl ester and derivatives thereof | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110144352-A1 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYCLIC ACID METHYL ESTER AND DERIVATIVES THEREOF | NOVARTIS AG (CH) | 2011-06-16 | — | — | US | disclosed |
| US-20110144352-A1 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYCLIC ACID METHYL ESTER AND DERIVATIVES THEREOF | NOVARTIS AG (CH) | 2011-06-16 | — | — | US | disclosed |
| US-20110144352-A1 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYCLIC ACID METHYL ESTER AND DERIVATIVES THEREOF | NOVARTIS AG (CH) | 2011-06-16 | — | — | US | disclosed |
| EP-2315748-A1 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYLIC ACID METHYL ESTER AND DERIVATIVES THEREOF | Novartis AG (CH) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010018154-A1 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYLIC ACID METHYL ESTER AND DERIVATIVES THEREOF | NOVARTIS AG (CH) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018154-A1 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYLIC ACID METHYL ESTER AND DERIVATIVES THEREOF | NOVARTIS AG (CH) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144352-A1 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYCLIC ACID METHYL ESTER AND DERIVATIVES THEREOF | KMO, IDO1, ALKBH3 | MAPK1 2679/4885SIGMAR1 628/4885MAPT 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.